Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Radiotherapy in Cutaneous Squamous Cell Carcinoma
NCT05085496Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Apr 2022
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in cutaneous squamous cell carcinoma (cSCC), sponsored by City of Hope. Primary endpoints: Dose Limiting Toxicity at 3 weeks and Incidence of Adverse Events at 90 days. Started Apr 2022; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05085496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085496.